These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 22146386)

  • 1. Relevance of T2 signal changes in the assessment of progression of glioblastoma according to the Response Assessment in Neurooncology criteria.
    Radbruch A; Lutz K; Wiestler B; Bäumer P; Heiland S; Wick W; Bendszus M
    Neuro Oncol; 2012 Feb; 14(2):222-9. PubMed ID: 22146386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deep-learning-based synthesis of post-contrast T1-weighted MRI for tumour response assessment in neuro-oncology: a multicentre, retrospective cohort study.
    Jayachandran Preetha C; Meredig H; Brugnara G; Mahmutoglu MA; Foltyn M; Isensee F; Kessler T; Pflüger I; Schell M; Neuberger U; Petersen J; Wick A; Heiland S; Debus J; Platten M; Idbaih A; Brandes AA; Winkler F; van den Bent MJ; Nabors B; Stupp R; Maier-Hein KH; Gorlia T; Tonn JC; Weller M; Wick W; Bendszus M; Vollmuth P
    Lancet Digit Health; 2021 Dec; 3(12):e784-e794. PubMed ID: 34688602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serial MR imaging of intracranial metastases after radiosurgery.
    Hawighorst H; Essig M; Debus J; Knopp MV; Engenhart-Cabilic R; Schönberg SO; Brix G; Zuna I; van Kaick G
    Magn Reson Imaging; 1997; 15(10):1121-32. PubMed ID: 9408133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infiltrative patterns of glioblastoma: Identification of tumor progress using apparent diffusion coefficient histograms.
    Lutz K; Wiestler B; Graf M; Bäumer P; Floca R; Schlemmer HP; Heiland S; Wick W; Bendszus M; Radbruch A
    J Magn Reson Imaging; 2014 May; 39(5):1096-103. PubMed ID: 24115401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma.
    Hutterer M; Nowosielski M; Putzer D; Waitz D; Tinkhauser G; Kostron H; Muigg A; Virgolini IJ; Staffen W; Trinka E; Gotwald T; Jacobs AH; Stockhammer G
    J Nucl Med; 2011 Jun; 52(6):856-64. PubMed ID: 21622893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between contrast enhancement on fluid-attenuated inversion recovery MR sequences and signal intensity on T2-weighted MR images: visual evaluation of brain tumors.
    Kubota T; Yamada K; Kizu O; Hirota T; Ito H; Ishihara K; Nishimura T
    J Magn Reson Imaging; 2005 Jun; 21(6):694-700. PubMed ID: 15906343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria.
    Gállego Pérez-Larraya J; Lahutte M; Petrirena G; Reyes-Botero G; González-Aguilar A; Houillier C; Guillevin R; Sanson M; Hoang-Xuan K; Delattre JY
    Neuro Oncol; 2012 May; 14(5):667-73. PubMed ID: 22492961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Refinement of response assessment in neuro-oncology (RANO) using non-enhancing lesion type and contrast enhancement evolution pattern in IDH wild-type glioblastomas.
    Moon HH; Kim HS; Park JE; Kim YH; Kim JH
    BMC Cancer; 2021 Jun; 21(1):654. PubMed ID: 34074252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility and Tumor Size Changes During the Time Course of Standard Treatment in Recurrent Glioblastoma.
    van Leyen K; Roelcke U; Gruber P; Remonda L; Berberat J
    J Neuroimaging; 2019 Sep; 29(5):645-649. PubMed ID: 31112344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response Assessment in Neuro-Oncology criteria, contrast enhancement and perfusion MRI for assessing progression in glioblastoma.
    Tensaouti F; Khalifa J; Lusque A; Plas B; Lotterie JA; Berry I; Laprie A; Cohen-Jonathan Moyal E; Lubrano V
    Neuroradiology; 2017 Oct; 59(10):1013-1020. PubMed ID: 28842741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma.
    Aghi M; Gaviani P; Henson JW; Batchelor TT; Louis DN; Barker FG
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8600-5. PubMed ID: 16361543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Voxel-Wise Analysis of Fluoroethyltyrosine PET and MRI in the Assessment of Recurrent Glioblastoma During Antiangiogenic Therapy.
    George E; Kijewski MF; Dubey S; Belanger AP; Reardon DA; Wen PY; Kesari S; Horky L; Park MA; Huang RY
    AJR Am J Roentgenol; 2018 Dec; 211(6):1342-1347. PubMed ID: 30332289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Robust texture features for response monitoring of glioblastoma multiforme on T1-weighted and T2-FLAIR MR images: a preliminary investigation in terms of identification and segmentation.
    Assefa D; Keller H; Ménard C; Laperriere N; Ferrari RJ; Yeung I
    Med Phys; 2010 Apr; 37(4):1722-36. PubMed ID: 20443493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Early Response to Anti-Angiogenic Therapy in Recurrent Glioblastoma: Amide Proton Transfer-weighted and Perfusion-weighted MRI compared with Diffusion-weighted MRI.
    Park JE; Kim HS; Park SY; Jung SC; Kim JH; Heo HY
    Radiology; 2020 May; 295(2):397-406. PubMed ID: 32154775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiologic progression of glioblastoma under therapy-an exploratory analysis of AVAglio.
    Nowosielski M; Ellingson BM; Chinot OL; Garcia J; Revil C; Radbruch A; Nishikawa R; Mason WP; Henriksson R; Saran F; Kickingereder P; Platten M; Sandmann T; Abrey LE; Cloughesy TF; Bendszus M; Wick W
    Neuro Oncol; 2018 Mar; 20(4):557-566. PubMed ID: 29016943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab.
    Huang RY; Rahman R; Ballman KV; Felten SJ; Anderson SK; Ellingson BM; Nayak L; Lee EQ; Abrey LE; Galanis E; Reardon DA; Pope WB; Cloughesy TF; Wen PY
    Clin Cancer Res; 2016 Feb; 22(3):575-81. PubMed ID: 26490307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic Contrast-Enhanced MR Imaging of Nonenhancing T2 High-Signal-Intensity Lesions in Baseline and Posttreatment Glioblastoma: Temporal Change and Prognostic Value.
    Hwang I; Choi SH; Park CK; Kim TM; Park SH; Won JK; Kim IH; Lee ST; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH
    AJNR Am J Neuroradiol; 2020 Jan; 41(1):49-56. PubMed ID: 31806595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perfusion and diffusion MRI of glioblastoma progression in a four-year prospective temozolomide clinical trial.
    Leimgruber A; Ostermann S; Yeon EJ; Buff E; Maeder PP; Stupp R; Meuli RA
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):869-75. PubMed ID: 16226399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [HIRE (high intensity reduction). New cerebrospinal fluid suppressed T2-weighted imaging sequence].
    Essig M; Deimling M; Schoenberg SO; Debus J; Knopp MV; van Kaick G
    Radiologe; 2000 Dec; 40(12):1163-71. PubMed ID: 11197935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical target volume delineation in glioblastomas: pre-operative versus post-operative/pre-radiotherapy MRI.
    Farace P; Giri MG; Meliadò G; Amelio D; Widesott L; Ricciardi GK; Dall'Oglio S; Rizzotti A; Sbarbati A; Beltramello A; Maluta S; Amichetti M
    Br J Radiol; 2011 Mar; 84(999):271-8. PubMed ID: 21045069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.